N-(2,5-Dimethylphenyl)-4-(2-naphthyl)-2,4-dioxo-3-(3-oxo-1,3-dihydro-2-benzofuran-1-yl)butanamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(2,5-Dimethylphenyl)-4-(2-naphthyl)-2,4-dioxo-3-(3-oxo-1,3-dihydro-2-benzofuran-1-yl)butanamide
• 英文别名: N-(2,5-dimethylphenyl)-4-naphthalen-2-yl-2,4-dioxo-3-(3-oxo-1H-2-benzofuran-1-yl)butanamide
• 化学式: C₃₀H₂₃NO₅
• 分子量: 477.5
• InChiKey: KDVUAQJLFSKMCS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  36
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  89.5
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Targeting Mcl-1 to enhance DNA replication stress sensitivity for cancer therapy
  申请人：Emory University

  公开号：US11524000B2

  公开（公告）日：2022-12-13

  This disclosure relates to inhibitors of Mcl-1 stimulated homologous recombination (HR) DNA repair and uses for treating cancer. In certain embodiments, this disclosure relates to methods of treating cancer comprising administering an inhibitor of Mcl-1 in combination with other anti-cancer agents, e.g., that induce DNA replication stress. In certain embodiments, this disclosure relates to methods of treating cancer comprising administering compounds disclosed herein in combination with hydroxyurea, olaparib, or combinations thereof.

  本公开涉及Mcl-1刺激同源重组（HR）DNA修复的抑制剂和治疗癌症的用途。 在某些实施方案中，本公开涉及治疗癌症的方法，包括将 Mcl-1 抑制剂与其它抗癌剂（如诱导 DNA 复制应激的抗癌剂）联合使用。 在某些实施方案中，本公开涉及治疗癌症的方法，包括施用本文公开的化合物与羟基脲、奥拉帕利或其组合。
• INHIBITORS OF MCL-1, COMPOSITIONS, AND USES IN MANAGING CANCER
  申请人：Emory University

  公开号：EP3700524A1

  公开（公告）日：2020-09-02
• Targeting Mcl-1 to Enhance DNA Replication Stress Sensitivity for Cancer Therapy
  申请人：Emory University

  公开号：US20200316011A1

  公开（公告）日：2020-10-08

  This disclosure relates to inhibitors of Mcl-1 stimulated homologous recombination (HR) DNA repair and uses for treating cancer. In certain embodiments, this disclosure relates to methods of treating cancer comprising administering an inhibitor of Mcl-1 in combination with other anti-cancer agents, e.g., that induce DNA replication stress. In certain embodiments, this disclosure relates to methods of treating cancer comprising administering compounds disclosed herein in combination with hydroxyurea, olaparib, or combinations thereof.